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A B S T R A C T
The increased number of annotated bacterial genomes provides a vast resource for genomemining. Several
bacterial natural products with epoxide groups have been identiﬁed as pre-mRNA spliceosome inhibi-
tors and antitumor compounds through genomemining. These epoxide-containing natural products feature
a common biosynthetic characteristic that cytochrome P450s (CYPs) and its patterns such as epoxidases
are employed in the tailoring reactions. The tailoring enzyme patterns are essential to both biological
activities and structural diversity of natural products, and can be used for enzyme pattern-based genome
mining. Recent development of direct cloning, heterologous expression, manipulation of the biosynthet-
ic pathways and the CRISPR-CAS9 system have provided molecular biology tools to turn on or pull out
nascent biosynthetic gene clusters to generate a microbial natural product library. This review focuses
on a library of epoxide-containing natural products and their associated CYPs, with the intention to provide
strategies on diversifying the structures of CYP-catalyzed bioactive natural products. It is conceivable that
a library of diversiﬁed bioactive natural products will be created by pattern-based genome mining, direct
cloning and heterologous expression as well as the genomic manipulation.
© 2016 The authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
“Discovery consists of seeing what everybody else has seen, and
thinking what nobody else has thought.”
— Nobel laureate Albert von Szent-Gyorgyi
1. Introduction
The conception of the natural product library originated from
the advocation for the Biological Resource Center (BRC) via the Or-
ganization for the Economic Cooperation and Development (OECD)
in 1999.1 During the past 15 years, the production of a library of
microbial natural products has been mainly driven by the devel-
opment of high-throughput screening methods and the increasing
number of reported marine natural products.2–4 Broadly speaking,
researches on natural product libraries have included the activi-
ties of creating a genomic DNA prioritized strain library,5 a
metagenome library,6,7 a combinational library,8 a crude extract
library,9–11 a fraction library12–14 and a pure compound library.15 Ad-
ditionally, the bioactive compound library is commercially available
from Selleckchem,16 OTAVA17 and Cromadex.18 Strategies for devel-
oping a high quality microbial natural product library include
diversiﬁcation and de-replication of strain, natural product struc-
tures and high throughput screening methods.2,19–23 Even so, the low
outcomes from the creation of a crude extract library and a frac-
tion library are far from the expectation in drug discovery. These
facts have diminished the interests of big pharma in the natural
product library.24
Nature is always full of diversity and natural product biosyn-
thesis is no exception. The “co-linearity” rule, and the diversity and
variations in nonribosomal peptide synthetases (NRPSs), polyketide
synthases (PKSs), hybrid NRPS/PKS systems and the beyond have
been greatly explored.25–31 During last two decades, well over hun-
dreds of natural product biosynthetic pathways and thousands of
natural scaffolds such as nonribosomal peptide, polyketide, terpe-
noid and oligosaccharide have been characterized.32,33 Except for the
enzymes that catalyze formation of chemical scaffolds, there is a
group of enzymes that decorate the functional group density, acting
sequentially to transfer the building blocks into complex molecu-
lar structures. The tailoring enzymes can be classiﬁed into
nonoxidative and oxidative enzymes. Nonoxidative enzymes include
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acyltransferases, methyltransferases and glycosyltransferases, while
oxidative enzymes encompass those who introduce water-
solubilizing oxygen functionalities during maturation and are
probably most consequential for introduction of both scaffold and
functional group complexity. While considering how to diversify
nature’s small molecule inventory, the oxygenase enzymes have
proven to be most valuable to characterize with the twin goals of
prediction of new natural product scaffolds and combinatorial en-
gineering of intermediates.33,34 The most prominent of the oxidative
enzymes are the heme iron cytochrome P450 (CYPs) monoxygenases
found in microbes such as Streptomyces species,35 Bacillus species36
and Cyanobacteria,37 etc.38
Traditionally, natural product genome mining means “use anal-
ysis of DNA sequence data to predict structural elements of new
natural products and then use this information to design strate-
gies for rapidly identifying, purifying, and structurally characterizing
the compounds”.39,40 However, the peculiarities of biosynthetic path-
ways indicate that textbook “co-linearity” rules cannot be applied
to deduce structures from all DNA data.41,42 Thanks to the devel-
opment of gene cluster prediction software such as antiSMASH,43
genomemining has become a quick and inexpensive way to analyze
the biosynthetic potential of sequenced microbes. The current
genome mining approaches include sequence-based genome
mining,44,45 bioactivity-guided genome mining,46 enzyme-based
genome mining,47 pattern-based genome mining48,49 and genome
neighborhood network analysis.50,51 Sequence-based genomemining
is designed to detect and extract carboxyl (C) – and keto-synthase
(KS) – domains from DNA or amino acid sequence data. The high
degrees of sequence similarity (E-value <10e−40 for eSNAPD or 85–
90% protein sequence identity for NaPDoS) suggest that identiﬁed
biosynthetic gene clusters are responsible for the biosynthesis of
similar natural products resulting from reference gene clusters.6,7,44,52
For bioactivity-guided genomemining, the conserved structuralmotif
of bioactive natural products can be used as a reference to perform
genome mining. For example, the enediyne PKS (PKSE) is pro-
posed to be involved in the formation of the highly reactive
chromophore ring structure (or “warhead”) found in all enediynes.
By PKSE based genomemining, the enediyne biosynthetic gene clus-
ters have been identiﬁed from sequenced actinomycete genomes.53
FK228 is an antitumor drug with tumor cytotoxicity resulting from
the functional disulﬁde group, which is catalyzed by the FAD-
dependent disulﬁde oxidoreductase.54,55 BLAST analysis of FAD-
dependent disulﬁde oxidoreductase has led to the discovery of a
homologous gene cluster of thailandepsins in Burkholderia
thailandensis E264.56 Enzyme-based genome mining searches con-
served synthase domains against the NCBI database of sequenced
bacterial genomes in order to obtain the presumptive enzyme
sequences.47 The “pattern-based genome mining” refers to the con-
nection of MS/MS fragmentation pattern to the biosynthetic
pathways genome mining and de-replication of certain bacterial
species. For example, the MS/MS fragmentation pattern of the
827.492 for arenicolide A production was used to identify the
uncharacterized gene cluster in S. paciﬁca strains CNQ-748 and
CNT-138.49 The “genome neighborhood networks (GNN) analysis”
is a bioinformatics strategy to predict enzymatic functions on a large
scale based on their genomic context. In this case, bioinformatics
of PepM and phosphonate GNNwere applied for 278 sequenced bac-
terial genomes and led to the discovery of 19 new phosphonate
natural products.57 Enediyne GNNs were generated for the virtual
screening of the sequenced bacterial genomes resulted in 87 po-
tential enediyne gene clusters from 78 different bacteria strains.50
The pattern-based genome mining and the genome neighborhood
analysis provide a comprehensive method to identify the biosyn-
thetic gene cluster of sequenced bacterial strains.
With the physiological and medical Nobel Prize awarding to
natural product avermectin and artemisinin, the discovery of natural
products has entered a golden age.58 Our long term goal is to create
a high quality, diversiﬁed natural product library. In the postgenomic
era, the challenges to generate a microbial natural product library
have been switched from the traditional de-replication strategies
to issues of how to translate the annotated biosynthetic gene clus-
ters of interest to a bioactive natural product library. The current
review will focus on genome mining of CYPs which are involved in
the biosynthetic gene clusters of bacterial secondary metabolites,
especially those with epoxide functional groups, with an inten-
tion to share the considerations to build a diversiﬁed natural product
library through CYP pattern-based genome mining, direct cloning
and heterologous expression, and genome manipulation.
2. Genome mining of CYP-catalyzed bacterial natural products
This section will cover the introduction of CYP, two genome
mining methods, and application of genome mining in two genera.
2.1. The importance of microbial CYPs
Microbial natural products catalyzed by CYP biosynthetic path-
ways have diversiﬁed biological activities including antitumor
activities, antibacterial activities, antifungal activities, anti-HIV ac-
tivities, anti-parasitic and anti-cholesterol activities. Natural products
such as pladienolides/FD-895,59,60 GEX1/herboxidiene,61 FR901464
(FR)/spliceostatins/thailanstatins62 (Fig. 1A) are known to have an-
titumor activities by targeting pre-mRNA spliceosome. Speciﬁcally,
pladienolide B and spliceostatin A have been reported to express
their antiproliferative activities against tumor cells at the nM range
by targeting the splicing factor 3B subunit 1 (SF3B1) with the help
of three-membered epoxide groups. Furthermore, CYP-catalyzed
natural products with antitumor activitiesmay have differentmecha-
nisms. For instance, epothilone A expresses the tubulin-binding
activity,63 griseorhodin A is telomerase inhibitor,64 tirandamycin is
RNA polymerase inhibitor65 and epoxomicin is proteasome-
inhibitor,66 etc (Fig. 1B).
Microbial CYPs are one of the most widely distributed groups
of tailoring enzymes to catalyze the formation of the ﬁnal bioactive
natural products.31,35,37,67–69 CYPs catalyze the hydroxylation and/
or epoxidation reactions in the late stages of biosynthesis after
macrolide formation by PKSs.70–72 Reactions catalyzed by CYP
monooxygenases include hydroxylation of saturated C—H bonds,
epoxidation of C=C double bonds, and oxidative decarboxylation
(Table 1).106 For example, The CYP PldB hydroxylates 6-deoxy
pladienolide B to pladienolide B in the pladienolide biosynthetic
pathway.59 The CYP HerG catalyzes the stereospeciﬁc hydrox-
ylation at C-18 of herboxidiene.61 For FR biosynthesis, the CYP Fr9R
is not only involved in the hydroxylation at C-4 of FR901464, but
is also related to the formation of the hemiketal group at C-1.62 CYPs
in the biosynthetic pathways of natural products often work to-
gether with its patterns such as transferases and epoxidases to
catalyze the production of epoxide groups. Moreover, dual-function
CYPs have been reported to catalyze sequential epoxidation and hy-
droxylation of the same substrate.65,88,107
2.2. Bioinformatics of microbial CYPs
The information on three-dimensional structures is essential to
understand the molecular basis for substrate recognition and speci-
ﬁcity of CYPs. It is universally thought that three elements are
essential in all CYPs sequences: (a) the conserved cysteine, which
is the ﬁfth ligand to the heme Fe atom and can be represented as
FXXGXXXCXG, (b) the EXXR motif forming a charge pair in the K
helix (possibly involved in heme binding) and (c) overall CYP fold
topology, including stability.108 However, there are some unusual
examples for bacterial CYPs, such as variations at conserved motifs,
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heme incorporation and topology, substrate binding and
functionalities. For example, the amino acid sequence of CYP157C1
contains EQSLW in place of the conserved EXXR.109 The conserved
threonine in CYP107A1 is not present and a hydroxyl group of the
substrate 6-deoxyerythronolide B can directly donate a hydrogen
bond to the Fe-linked dioxygen for proton transfer.76 Different from
CYP107A1, CYP158A2 binds two molecules of ﬂaviolin in its active
site, and the 2-OH group of ﬂaviolin is responsible for anchoring
the substrate in the active site, while the 5-OH and 7-OH stabilize
water molecules which are important for catalysis.110
For the discovery of bacterial CYPs in sequenced genomes, genes
encoding the CYP heme binding domain (FXXGXXXCXG) can be
screened for the presence of a highly conserved threonine in the
putative I-helix, which is proposed to be involved in CYP oxygen
activation in most CYPs, and the conserved EXXR motif is located
in the K-helix. The sequences of polypeptides containing all three
Table 1
CYPs involved in the biosynthesis of microbial natural products.
P450 enzymes No. amino acid (AA) Accession no. Match in the databasea Reference
CYP name as annotated Protein identiﬁer Identity% AA overlap
Hydroxylation of saturated C—H bonds
AmphL 396 AAK73504 CYP107E AAK73504 100% 396 73
AziB1 401 B4XY99.1 CYP107-like WP_018771011.1 34% 388 74
ChmPI 407 AAS79447 CYP107B AAS79447 100% 407 75
EpnK 401 AHB38512 CYP162-like WP_030872520.1 40% 399 66
EryF 404 Q00441.2 CYP107A WP_009950397.1 100% 404 76
EryK 397 CYP113A1 CYP113A-like WP_009950895.1 100% 397 77
HerG 422 AEZ64507 CYP107B-like WP_016577953.1 48% 404 61
MeiE 459 AAM97314 CYP171A AAM97314 100% 459 78
MycCI 383 BAC57023 CYP105U BAC57023 100% 383 79
NcsB3 410 AAM77997 CYP154J AAM77997 100% 410 80
NysL 394 AAF71769 CYP107E AAF71769 100% 394 81
OxyD 396 CCD33151 CYP146A CCD33151 100% 396 82
PikC 416 O87605 CYP107L AAC64105 100% 416 83
PldB 399 BAH02272 CYP107B-like BAH02272 100% 399 59
PteC 399 BAC68123 CYP105P1 WP_010981850.1 100% 399 84
TylHI 436 AAD41818 CYP105U AAD41818 100% 436 85
TylI 417 AAA21341 CYP107-like AAA21341 100% 417 86
ZbmVIIc 416 ACG60779 CYP185-like WP_030613068.1 51% 430 78
TxtC 395 AAL36838.1 CYP105A WP_009073396.1 41% 406 87
Dual function, hydroxylation and epoxidation
GsfF 414 BAJ16472 CYP105A BAJ16472 100% 414 88
MycG 397 BAA03672 CYP107B BAA03672 100% 397 89
Fma-P450 400 AHL19974 –b 90
Fr9R 482 AIC32704 CYP136-like WP_022984814.1 32% 455 62
PenD 298 ADO85592 – 91
PntD 299 ADO85576 – 92
TamI 413 ADC79647.1 CYP107B-like ADC79647.1 100% 413 65
TstR 482 AGN11891 CYP136-like BAP15297 33% 455 93
Catalyze epoxidation
Asm30 1005 AAM54108 CYP102F AAM54108 100% 1005 94
ChmPII 401 AAS79446 CYP107B AAS79446 100% 401 75
EpnI 431 AHB38510 CYP107B-like WP_030776170.1 48% 412 66
EpoK 419 Q9KIZ4 CYP167A Q9KIZ4 100% 419 63
EpxC 425 AHB38496 CYP107B-like WP_020576451.1 42% 406 66
GrhO3 416 AAM33670 CYP105-like AAM33670 100% 416 64
HedR 409 AAP85338 CYP105-like AAP85338 100% 409 95
OleP 407 AAA92553 CYP107B AAA92553 100% 407 96
PimD 397 CAC20932 CYP107E CAC20932 100% 397 97
PimG 398 CAC20928 CYP105H CAC20928 100% 398 97
TamI 413 ADC79647 CYP107B-like ADC79647 100% 413 98
Oxidation of methyl group
AmphN 399 AAK73509 CYP105H AAK73509 100% 399 99
NysN 398 AAF71771 CYP105H AAF71771 100% 398 81
C-C coupling
DynOrf19 403 ACB47070 CYP107M WP_015621195.1 51% 398 100
HmtS 397 CBZ42153 CYP113A WP_030360446.1 52% 398 101
OxyB 398 AAL90878 CYP165B Q8RN04 100% 398 102
OxyC 406 AAL90879 CYP165B Q8RN03 100% 406 103
C-N-C coupling
DynE10 400 ACB47071 CYP107B WP_029899036.1 53% 400 100
SpcN 390 AGL96571 CYP244A AGL96571 100% 390 104
Catalyzes the nitration using NO and O2
TxtE 406 ELP66108.1 CYPP450TXTE ELP66108.1 100% 406 87
Oxidative decarboxylation
HmtN 419 4E2P_A CYP113A 4E2P_A 100% 419 101
HmtT 418 4GGV_A CYP113A 4GGV_A 100% 418 101
Mei-Orf4 398 ADC45514 CYP107-like ADC45514 100% 398 78
StaP 426 ABI94389 CYP245A ABI94389 100% 426 105
SpcP 427 AGL96575 CYP245A AGL96575 100% 427 104
a CYP names as annotated at website: https://cyped.biocatnet.de/.
b Not found in database.
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motifs can be further used as queries for BLAST searches of the
GenBank non-redundant protein database (www.ncbi.nlm.nih.gov/
BLAST/) to identify their closest homologues in other organisms and
tentatively assign the CYP proteins to subfamilies. Brieﬂy, >40% of
amino acid sequence identity places a CYP in the same family and
>55% places it in the same subfamily.111 Besides GenBank, there is
a CYPED database which scours Genbank by BLAST-searching and
retrieving the CYP sequences to put in their database
(https://cyped.biocatnet.de/).112–115 This database contains the most
bacterial CYPs (Table 1) that are involved in the biosynthesis of
bioactive natural products (Fig. 1). There is also another online CYP
database (http://drnelson.uthsc.edu/CytochromeP450.html), which
contains1042 bacterial CYP genes.
2.3. The logic for CYP pattern-based genome mining
There is evidence that CYPs can be used for genome mining for
pre-mRNA spliceosome inhibitors. First, all current pre-mRNA
spliceosome inhibitors are epoxide-containing natural products
(Fig. 1A) whose biosynthesis gene clusters contain genes encod-
ing putative CYP oxygenases or epoxidases. It has been reported that
the presence of epoxide group is important in conferring activity
to FR analogues.116,117 Second, CYPs may not directly be involved in
the formation of some epoxide groups,70,118 but CYPs are present in
the relevant biosynthetic gene clusters (Fig. 2). For example, in a
recent metagenome mining report, all six epoxyketone gene clus-
ters contain CYPs,119 indicating that CYP-containing gene clusters
may be a rich source for the biosynthesis of epoxide compounds.
Third, even antitumor activities of CYP-catalyzed compounds are
related to different mechanisms. Small molecule screenings iden-
tiﬁed that oxaspiro compounds (the farnesyltransferase inhibitor
manumycin A analogues) are pre-mRNA splicing inhibitors.120 In ad-
dition, a number of compounds such as the CYP-related non-
epoxide compounds staurosporine (kinase inhibitor), are novel
inhibitors of spliceosome assembly.120 Fourth, homologous CYPs can
be identiﬁed through genomemining by a 50–60% similarity except
for the 80%–90% rule for PKS and nonribosomal peptide synthe-
tase (NRPS) domain searching. For example, BLAST analysis
demonstrated a 50% identity between CYPs PldB and HerG from
pladienolide and herboxidiene (both are pre-mRNA spliceosome in-
hibitors), respectively.121 In the biosynthesis of FD-891, the CYP GfsF
showed 57% identity to the CYPmonooxygenase Mﬂv2418.88 Finally,
the CYP gene can be used as a signature gene for gene cluster cloning
and gene identiﬁcation.59 However, CYP pattern should be consid-
ered because CYPs and other tailoring enzymes such as transferases
and epoxidases act together on the released PKS or NRPS
megasynthases68,122,123 (Fig. 3).
2.4. Discovery of thailanstatins from Burkholderia sp.
Recently, the genus Burkholderia has attracted the attention of
several research groups to employ different genome mining strat-
egies for the study of bioactive natural products.124 Among those
products, FR is a general spliceosome inhibitor discovered in 1992
from Pseudomonas sp. No. 2663,125–127 now identiﬁed as Burkholderia
sp. FERM BP3421.62 There are three oxygenase activities encoded
in FR gene cluster: (a) the ﬂavin-dependent monooxygenase (FMO)
domain in the last module of fr9GH, (b) the CYP encoded by fr9R,
and (c) the Fe(II)/α-ketoglutarate-dependent dioxygenase encoded
by fr9P. The hemiketal FR is mainly biosynthesized through the
epoxidation at C3 by the FMO domain of Fr9GH, the hydrox-
ylation at C-4 by the Fr9R, the hydroxylation at C-1 by Fr9P and
then decarboxylation.62 First, BLAST analysis shows that Fr9R has
a high identity (82%) to TstR in the sequenced genome of
B. thailandensisMSMB43 (currently being described as “Burkholderia
hymptydooensis”).93,128,129 Second, Fr9K is a key 3-hydroxy-3-
methylglutaryl-CoA synthase (HCS) homologue-enzyme catalyzing
the transfer of —CH2COO— from acyl-S-acyl carrier protein (ACP)
to a β-ketothioester polyketide intermediate. Fr9K has a high iden-
tity (87%) to one of the enzymes (TstK) predicted from the genome
of B. thailandensis MSMB43. Further, a regulator gene expression
studies for optimization of production media, and targeted isola-
tion and puriﬁcation efforts toward diene compounds (UV235 nm),
led to the discovery of three compounds called thailanstatins93 and
a group of similar or identical compounds called spliceostatins130,131
(Fig. 4). Particularly, thailanstatin A contains a carboxyl group, which
not only makes it more stable than FR in PBS solution, but also
leads to increased activities compared to FR when carboxylic groups
were esteriﬁed (with enhanced membrane permeability).130
2.5. Kutzneria species are potential resources of CYP-catalyzed
compounds
In the Actinobacteria phylum, the genus Kutzneria is a minor
branch of the Pseudonocardiaceae family, currently containing
eight species (Fig. 5). Only aculeximycin and kutznerides are known
to be produced by Kutzneria albida DSM 43870T and Kutzneria sp.
744, respectively.132,133 Genome mining of Kutzneria species sug-
gests that they could produce compounds similar to the previously
reported pre-mRNA spliceosome inhibitors and a group of inter-
esting CYP catalyzed compounds. For example, the pladienolide
biosynthetic gene cluster has only four genes (including the pldB
CYP gene, and the putative epoxidase encoding gene pldD) besides
the PKS genes.59 Inspired by the successful discovery of thailanstatins,
pladienolide B CYP monooxygenase-based bioinformatics analysis
was conducted and revealed that the Kutzneria sp. 744 genome
contains the most homologous (78%) enzyme KUTG_06291
(EWM16617) when CYP PldB sequence was used as input for
homology search of the GeneBank (Fig. 6). Therefore, the genus
Kutzneria was postulated to produce compounds similar to
pladienolide. However, there are still a lot of gaps in the se-
quenced genome of Kutzneria sp. 744.
Kutzneria albida DSM 43870T is the only Kutzneria strain with a
complete sequenced genome. So far, the K. albida genome (9.87Mb)
is among the largest actinobacterial genomes sequenced.134 Thus,
Kutzneria albida DSM 43870T was selected for further phyloge-
netic analysis of CYPs in parallel with a library of 44 CYPs originate
from biosynthetic gene clusters of 32 bioactive natural
products.37,61–64,73,74,76,78,80–86,88–92,94–100,102–105 AntiSMASH analysis re-
vealed that the K. albida DSM 43870T genome encodes 47
biosynthetic gene clusters which contain at least 13 different CYPs
distributed in eight gene clusters (GC4, GC10, GC11, GC18, GC19,
GC33, GC34 and GC40)134 (Fig. 5, Table S1). Among those gene clus-
ters, only GC40 is known to be responsible for the biosynthesis of
aculeximycin. The CYP KALB_6568 is predicted to be responsible for
catalyzing the formation of C14 hydroxyl group. However, the com-
pounds biosynthesized by the other CYP-related gene clusters are
not known yet. BLAST analysis (Fig. 2) suggests that in the K. albida
DSM 43870T genome, GC19 encodes compounds with CYP
(KALB_3944, possessing 99% identity to Mei-Orf4)-encoded func-
tional groups similar to meilingmycin78 and tirandamycin B98 (66%
identity to TamI). As for GC11, the 99% identity between CYP
KALB_3411 and Stap (in the staurosporine biosynthesis gene
cluster105) suggests that GC11 may be responsible for the biosyn-
thesis of compounds with functional groups formed by similar
oxidative decarboxylations. Additionally, antiSMASH analysis indi-
cates that GC11 has a 20% similarity to the biosynthetic gene clusters
of the pre-mRNA spliceosome inhibitor staurosporine. Similarly, the
99% identity between CYP KALB_3295 (in GC10) and Asm30 (CYP
in ansamitocin biosynthesis gene cluster94) implies that GC10 may
produce epoxide compounds similar to ansamitocin. Similar anal-
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Fig. 1. P450 related microbial natural compounds. Except for staurosporine, all the selected compounds are epoxide-containing compounds. Other epoxide compounds without
known biosynthetic pathways, such as antitumor compound trapoxin, are not listed. Panel A: Natural products with known spliceosome inhibitory activities; Panel B: Natural
products with other activities such as tubulin-binding compounds epothilone A, telomerase inhibitor griseorhodin A, RNA polymerase inhibitor tirandamycin and proteasome-
inhibitor epoxomicin, etc.
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ysis suggests that tirandamycin-like compounds may be produced
through GC19 based on the 66% identity between KALB_3945 and
TamI.98,135 Unfortunately, the 27% identity between KALB_5792 (in
GC33) and AziB1 (CYP in the azinomycin B biosynthetic gene
cluster74), and the 19% identity between KALB_5804 (in GC33) and
EpoK (CYP in the epothilone biosynthesis gene cluster63) make it
unpredictable for the natural products biosynthesized by GC33.
Except for Kutzneria albida DSM 43870T, another top ﬁve strains,
Actinoplanes sp. N902-109 (NC_021191.1),Micromonospora aurantiaca
ATCC 27029 (CP002162.1), Streptomyces violaceusniger Tu 4113
(CP002994.1), Streptomyces bingchenggensis BCW-1 (CP002047.1) and
Streptomyces sp. PVA 94-07 (CM002273.1), were prioritized through
CYP pattern-based genome mining of pladienolide biosynthetic
pathway. These strains have the potential CYP pattern pathways to
produce unknown compounds (Tables S2–S6).
3. Conceivable methods to translate biosynthetic pathways to
natural products
This section covers the methods (Fig. 7) or tools that have been
used or have the potential to be applied to translate biosynthetic
pathways to natural products.
3.1. Direct cloning and heterologous expression of biosynthetic gene
clusters
Heterologous expression was primarily used to avoid the lack
of genetic tools and regulatory complexity in native hosts via the
use of strains that are more amenable to engineering. Direct cloning,
genetic engineering and heterologous expression of microbial natural
product biosynthesis pathways were reviewed in 2013.136 The het-
erologous expression methods can also be borrowed from those for
the discovery of small molecules from metagenomics cosmid
library.7,137,138 The approaches to cloning targeted gene clusters di-
rectly from genomic DNA include RecE-mediated homologous
recombination,139 oriTdirected capture,140 transformation-associated
recombination (TAR)141–143 to facilitate functional expression ex-
periments and phageφBT1 integrase-mediated site-speciﬁc
recombination.144 Among those, TAR cloning in Saccharomyces
cerevisiae has been extensively applied to capture and express large
biosynthetic gene clusters from environmental DNA samples.145–147
Recently, the TAR direct cloning approach was used to clone tar-
geted whole gene cluster from rare actinomycetes and Gram-
negative bacteria. By using TAR, the targeted gene cluster was cloned
into plasmid pCAP01 by homologous recombination in Saccharo-
myces cerevisiae strain VL6-48 in order to obtain the captured vector,
and then the captured vector was transformed into the correspond-
ing host Streptomycete coelicolor and E. coli for rare actinomycete
and Gram-negative bacteria, respectively. An example is the het-
erologous production of lipopeptide taromycin A (from marine
actinomycete Saccharomonospora sp. CNQ-490) in Streptomycete
coelicolorM512142 and the heterologous production of alterochromide
lipopeptides (from Pseudoalteromonas piscicida JCM 20779) in E. coli
BL21 (DE3) utilizing native and E. coli-based T7 promoter
sequences.141 Since the development of a TAR-based genetic plat-
form allows for heterologous production of lipopeptides in different
hosts, efforts have been focused on the development of the high
throughput TAR capture method to express the pathway.141
Successful production of the desired products often requires an
optimal relationship of timing and ﬂux between primary and sec-
ondary cellular metabolism. Besides the use of genetic engineering
for the direct cloning of a whole gene cluster, there has been con-
siderable interest in the development of engineered bacterial strains
for eﬃcient heterologous production of secondary metabolites.148–151
For example, the deletion of a 1.4 Mb segment from the left
subtelomeric region of the 9.02Mb Streptomyces avermitilis genome
Fig. 2. Neighbor-joining tree of selected P450 enzymes including 13 putative P450
enzymes from Kutzneria species. CYPs catalyze epoxide formation (●), hydrox-
ylations (■), oxidation of methyl groups (♦), decarboxylations (▲) and C–C or CNC
formations (▼). The tree was generated by using MEGA6 using the neighbor joining
method. Signiﬁcant bootstrap values are indicated at the nodes. The scale bar rep-
resents 0.1mutational events per site. PldB, Fr9R, GfsF and StaP associated gene clusters
produce pre-mRNA spliceosome inhibitors pladienolid, FR901464, FD-891 and
staurosporine, respectively.
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resulted in the generation of two large-deletion mutants. By using
these large-deletionmutants, i.e., S. avermitilis SUKA17 or 22, twenty
of the entire biosynthetic gene clusters for secondary metabolites,
including aminoglycosides, nonribosomal peptides, polyketides and
terpeneswere successfully expressed.152 The biosynthetic gene cluster
of the polyketide pladienolide has been expressed in a deletion
mutant of Streptomyces avermitilis with an extra copy of the regu-
latory gene pldR under control of an alternative promoter.152 It is
worthy to note that the engineered hosts are not only useful for the
production of exogenous secondary metabolites, but they also fa-
cilitate scale-up production and preparation of promising natural
products due to their “clean” background.
3.2. Manipulation of the biosynthetic pathways
The recent approaches on the activation and up-regulation of mi-
crobial biosynthetic pathways for the discovery of natural products
have been reviewed.153,154 Except for these methods, there are four
types of research reports that may explain how to translate bio-
synthetic gene clusters to novel natural products by using synthetic
biology methods. First, optimized bioactive compounds can be pro-
duced by engineering the biosynthetic operon and reconstituting
the biosynthetic pathway. The group led by Müller and Brönstrup
successfully deleted the gene in hydroxymalonyl-CoA biosynthet-
ic operon of the bengamide biosynthetic gene cluster and inserted
a promoter on the expression construct pBen32. Heterologous ex-
pression of the modiﬁed biosynthetic gene cluster led to the
discovery of more potent compounds.155 Second, new compounds
with increased activities are produced by inactivation of CYP pattern
genes. Bills’ teamworks on the manipulation of pneumocandin bio-
synthetic pathway. They focused on the inactivation of three genes
(GLP450-1, GLP450-2, and GLOXY1) and generated 13 different
pneumocandin analogues that lack one, two, three, or four hy-
droxyl groups on 4R, 5R-dihydroxy-ornithine and 3S, 4S-dihydroxy-
homotyrosine of the parent hexapeptide. Among them, seven
analogues are previously unreported.156 Third, natural product ana-
logues can be produced by creating promoter-driven tailoring
enzyme constructs. Brady’s group created an ermE promoter cas-
Fig. 3. Pattern-based genome mining of homologous gene clusters of spliceosome inhibitors which contain CYPs. The biosynthetic gene clusters of thailanstatins (Acces-
sion no. KJ461964.1) and FR901464 (Accession no. JX307851.1), pladienolide (Accession no. AB435553.1) and herboxidiene (Accession no. JN671974.1) as well as staurosporine
(Accession no. AB088119.1) were used for the search of homologous gene clusters by using antiSMASH 3.0.
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Fig. 4. Genomemining protocol of Burkholderia thailandensisMSMB43 for thailanstatins/spliceostatins. Starting from the two key biosynthetic enzymes CYP Fr9R and 3-hydroxy-
3-methylglutaryl-CoA synthase (HCS) Fr9K that catalyze the formation of the hemiketal hydroxyl group and the epoxide group of FR901464, the homologous enzymes and
biosynthetic gene cluster of thailanstatin were predicted. The Reverse Transcriptional (RT)-PCR help to identify the optimum medium for the expression of regulatory gene
tstA. The novel compounds were ﬁnally obtained through microbial fermentation, natural product isolation and structural elucidation by tracking of the characteristic UV
absorption for the diene motif at UV235 nm.
Fig. 5. Phylogenetic tree for taxa of the genus Kutzneria and other antitumor compound-producing species (Streptomyces and Burkholderia). The tree was calculated from
complete 16S rRNA gene sequences using the neighbor joining method, illustrating the genus Kutzneria position relative to other selected species. All species are type strains
except for the strains Kutzneria sp. 744, Burkholderia sp., MSMB43 and MSMB121. The 16S RNA sequence of the pladienolide producer Streptomyces platensis Mer-11107 is
not available, but DNA hybridization suggests that Streptomyces platensis Mer-11107 has 87% similarity to the type strain CGMCC4.1975. Percentages at nodes represent
levels of bootstrap support from 1000 resampled datasets; Scale bar, 0.02 nucleotide substitutions per site.
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Fig. 6. Strategy for the discovery of novel compounds from Kutzneria species. By starting with the structure of pladienolide B, and moving through phylogenetic analysis of
the streptomycetes-related cytochrome P450s, Kutzneria species were selected for further analysis of P450-related polyketides. The genome sequencing of the closest strain
of Kutzneria sp. 744 was ﬁnished on February, 2014 without detailed annotation and there are still a lot of gaps waiting to be closed.
Fig. 7. Schematic representation of methods to translate biosynthetic pathways to novel natural products.
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sette, which was introduced to the upstream of the ﬁrst ORF of the
biosynthetic gene cluster of interest. Further introduction of the
cosmid containing the constitutively expressed tailoring operon into
S. toyocaensis:ΔStaL resulted in the production of three new
glycopeptides.44 Fourth, stable compounds with increased titer are
produced by engineering the CYP pathway. Researchers in Pﬁzer en-
gineered a pAE-PF29 vector which enabled the overexpression of
Fr9R encoded by CYP fr9R in Burkholderia sp. FERM BP-3421, and
led to the enhanced production of stable thailanstatin A from
spliceostatin C.157
3.3. Synthetic biology tool kits
Except for the four examples of genetic manipulations, synthet-
ic biology tools to edit bacterial genomes have been reviewed by
other researchers.158 The Clustered Regularly Interspaced Short Pal-
indromic Repeats and Cas proteins (CRISPR-Cas) systems are
composed of a powerful and broadly applicable set of tools to ma-
nipulate Streptomyces genomes. There are three research groups that
worked on the gene deletion of Streptomyces species by using dif-
ferent CRISPR-Cas toolkits. The group led by Zhao developed a
temperature-sensitive pCRISPomyces system, which is applicable
to the genome editing of Streptomyces lividans 66, Streptomyces
viridochromogenes DSM 40736 and Streptomyces albus J1074.159 Lee
and Webber’s group focused on the gene deletion eﬃciency of
actinorhodin biosynthetic gene cluster in Streptomyces coelicolor A3
by an engineered CRISPR-Cas system with improved eﬃciency.160
Sun’s team worked on the discovery of a novel CRISPR-Cas system
in combination with the counterselection system CodA(sm), and the
D314A mutant of cytosine deaminase, to delete the actinorhodin
biosynthetic gene cluster in Streptomyces coelicolorM145 genome.161
4. The advantages and challenges of the above mentioned
strategies
The advantages and challenges to generate a bioactive natural
product library by CYP pattern-based genome mining as com-
pared to the traditional strategies such as microbial fermentation
with different media and chromatographic fractionation for differ-
ent polarities can be summarized as follows.
4.1. Advantages
– CYP is a class of most important tailoring enzymes that can be
explored and exploited for the structural diversiﬁcation of
bioactive natural products.
– Genome mining is an eﬃcient method. The combination of PCR
screening and genomeminingwill prioritize the cryptic gene clus-
ters of interest for annotation and heterologous expression. This
is more eﬃcient when compared to the traditional conception
of one strain many active compounds (OSMAC).
– Genome mining can be used for large scale and high through-
putmethod to accelerate drug discovery, as exempliﬁed by a four-
year case study on genome mining of 10,000 actinomycetes for
19 novel phosphonic acid natural products.57
– Both heterologous expression and activation of cryptic path-
ways can generate novel compounds that have unique biological
activities but are diﬃcult to access using synthetic chemistry.
– CRISPR-cas9 enabled genome editing tools are very eﬃcient. First,
compared to the 5% (2/38) eﬃciency in the traditional
in-frame gene deletion method,62 the eﬃciency of the CRISPR-
Cas9 systems can be 100% without unwanted side- or off-
target effects.160 Second, CRISPR-Cas9 systems can overcome the
employment of the counter selectable marker for the selection
of double crossover mutants. Third, CRISPR-Cas9 systems can
avoid the scar sequence left at the target site and realize mul-
tiple gene deletions. Fourth, CRISPR/Cas system provides new
modularity, which can target the site of interest by inserting of
a short spacer into a CRISPR array/sgRNA construct. The inser-
tion can be achieved with high throughput using modern DNA
assembly techniques. CRISPR/Cas9 genome editing can shorten
the two-month period of previous gene deletion method to the
current 1–2 week time course.161
4.2. Main challenges
– How to prioritize the characterization of orphan biosynthetic gene
clusters, and how to rapidly connect genes to biosynthesized
small molecules will come with increase in DNA-sequenced
data.162
– Pathway manipulations in native hosts are subjected to the
genetic complexity of the bacteria. For example, researchers have
developed a procedure which takes about 10 days for the chro-
mosomal knock out of Gram-negative bacteria B. pseudomallei
by using the pheS-gat cassette-assisted by plasmid pKaKa2.163
However, this method is not applicable to the gene knockout of
another strain called B. gladioli, which requires another
pCR4Blunt-TOPO-based vector for the recombination assisted by
plasmid pKD46.164
– Up to now, Cas9 targeting is still limited by protospacer adja-
cent motif (PAM) sequences. Also, targeting eﬃciency is
site-dependent.
– Although the development of genetic manipulation tools could
greatly enhance the chances toward discovery and production
of natural products, a major challenge in the process of micro-
bial genome mining is to produce compounds in high titers.165
– Bacterial genomes are publically available but the accessibility
of strains of interest is limited due to the regulations of inter-
national or domestic properties. Decreasing DNA synthesis costs
and advances in DNA assembly could help to solve the issue with
limited material access. A larger fraction of strains that are iso-
lated in research labs worldwide will be the future challenge.166
5. Conclusion
The current review provides strategies on the discovery of a group
of epoxide-containing natural products (Fig. 8), highlights (1) CYP
and its pattern enzyme-based genomemining as a guidance for the
generation of a diversiﬁed natural product library, (2) direct cloning
and heterologous expression of biosynthetic pathways and genomic
manipulation methods and tools will translate the selected bio-
synthetic gene clusters to the bioactive natural product library. It
is worthy to note that tailoring reactions play important roles on
diversiﬁcations of scaffolds such as polyketide, peptide and hybrid
polyketide-peptide backbones, and often tailoring enzyme pat-
terns such as CYPs, ligases, Cyclases, ketoreductases, transferases,
and oxygenases can be used for genome mining. This advanced
genome mining will avoid the de-replications of biosynthetic gene
clusters to quickly identify the annotated biosynthetic gene clus-
ters from the vast pool of sequenced bacterial genomes. It is predicted
that we will be sequencing genomes for pennies as nearly as 2020
(https://youtu.be/j88APStUcp4). Synthetic biology tools pio-
neered by different researchers will be continuously developed
toward a high-throughput potential due to the increasing numbers
of sequenced bacterial genomes. This review also points out the po-
tential mechanisms and diversity of CYPs in the microbial
biosynthesis of natural product antitumor agents. The Kutzneria
strains, as rare actinobacterial species, can be explored and ex-
ploited for CYP catalyzed compounds, and can be used as a rich
resource for the diversiﬁcation of microbial CYPs.
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